Advanced

Efficacy of lixisenatide in patients with type 2 diabetes : A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials

Yabe, Daisuke; Ambos, Anu; Cariou, Bertrand; Duvnjak, Lea; Evans, Marc; González-Gálvez, Guillermo; Lin, Jay; Nikonova, Elena V.; de Pablos-Velasco, Pedro and Yale, Jean François, et al. (2016) In Journal of Diabetes and its Complications
Abstract

Aims: To evaluate the impact of β-cell function on the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D). Materials and methods: In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20. μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index. Results: Patients (N = 437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]),... (More)

Aims: To evaluate the impact of β-cell function on the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D). Materials and methods: In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20. μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index. Results: Patients (N = 437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]), -0.99 (-10.8), -0.87 (-9.5), -0.86 (-9.4), -0.83 (-9.1); and postprandial plasma glucose (PPG; mmol/L), -7.9, -5.6, -5.5, -4.3 (overall effect . P .

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
Antidiabetic drug, Beta cell, GLP-1 analog, Glycemic control, Type 2 diabetes
in
Journal of Diabetes and its Complications
publisher
Elsevier
external identifiers
  • Scopus:84971657481
ISSN
1056-8727
DOI
10.1016/j.jdiacomp.2016.05.018
language
English
LU publication?
yes
id
fe48458a-61f4-4eb3-b455-c2b1b082abc5
date added to LUP
2016-06-16 09:44:42
date last changed
2016-11-03 10:13:15
@misc{fe48458a-61f4-4eb3-b455-c2b1b082abc5,
  abstract     = {<p>Aims: To evaluate the impact of β-cell function on the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D). Materials and methods: In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20. μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index. Results: Patients (N = 437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]), -0.99 (-10.8), -0.87 (-9.5), -0.86 (-9.4), -0.83 (-9.1); and postprandial plasma glucose (PPG; mmol/L), -7.9, -5.6, -5.5, -4.3 (overall effect . P . </p>},
  author       = {Yabe, Daisuke and Ambos, Anu and Cariou, Bertrand and Duvnjak, Lea and Evans, Marc and González-Gálvez, Guillermo and Lin, Jay and Nikonova, Elena V. and de Pablos-Velasco, Pedro and Yale, Jean François and Ahrén, Bo},
  issn         = {1056-8727},
  keyword      = {Antidiabetic drug,Beta cell,GLP-1 analog,Glycemic control,Type 2 diabetes},
  language     = {eng},
  month        = {02},
  publisher    = {ARRAY(0x9b267a8)},
  series       = {Journal of Diabetes and its Complications},
  title        = {Efficacy of lixisenatide in patients with type 2 diabetes : A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials},
  url          = {http://dx.doi.org/10.1016/j.jdiacomp.2016.05.018},
  year         = {2016},
}